Early PCSK9 Inhibition in AMI Yields Plaque Regression
"Go early and go low" is an expert's response to the imaging results from PACMAN-AMI showing plaque reduction after AMI patients received alirobumab.
Source: medscape.com
Stay updated with breaking news from Pamelab Morris. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
"Go early and go low" is an expert's response to the imaging results from PACMAN-AMI showing plaque reduction after AMI patients received alirobumab.
The results add to growing enthusiasm for achieving the 'holy grail' of a lipoprotein(a)-specific lowering agent, but whether it will reduce cardiovascular risk remains unknown.
The multiverse exists as the ACC offers a traditional in-person meeting spanning all of cardiology paired with what could be a lasting legacy of the pandemic, a robust, parallel virtual experience.